About Panoptes Pharma
Panoptes Pharma is a Healthcare company based in Vienna (Austria) founded in 2013, and was acquired by EyeGate in December 2020. Small molecule therapies are developed for severe eye diseases. Panoptes Pharma has raised $1.62 million across 2 funding rounds from investors including Austria Wirtschaftsservice and EyeGate. The company was acqui-hired. Panoptes Pharma offers products and services including PP-001, Augentropfen, Injektionen, and Systemische Arzneimittel. Its focus areas include Life Sciences, Ophthalmology, Drugs and Diversified.
Company details
Panoptes Pharma was established in 2013 in Vienna, Austria, within the pharmaceutical sector. Small molecule-based treatments are developed for eye conditions with significant unmet needs, including autoimmune uveitis and inflammatory diseases. The lead candidate, PP-001, functions as a specific inhibitor of an enzyme in the de novo pyrimidine pathway and is undergoing preclinical trials for uveitis and viral conjunctivitis. Operations center on advancing these therapies through clinical development.
- Headquarters Vienna, Austria
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website panoptes-pharma.com
- Acquired by EyeGate (Dec 2020)
- Total Equity Funding$1.62M (USD)
in 2 rounds
- InvestorsAustria Wirtschaftsservice
& 1 more
- Acquired byEyeGate
(Dec 2020)
Products & Services of Panoptes Pharma
Panoptes Pharma offers a comprehensive portfolio of products and services, including PP-001, Augentropfen, Injektionen, and Systemische Arzneimittel.
Treats eye diseases like Uveitis and diabetic Retinopathy.
Provides treatment for eye conditions through topical application.
Delivers therapies for various medical issues via injection.
Offers treatments for conditions like erectile dysfunction.
Funding Insights of Panoptes Pharma
Panoptes Pharma has successfully raised a total of $1.62M across 2 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.62M
- Total Rounds 2
- First Round $1.62M
(Sep 2013)
- Investors Count 1
All 2 funding rounds of Panoptes Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2015 | Series A | – | – | ||
| Sep 2013 | $1.62M | Seed | – | – |
2 investors in total: 2 institutional.
Investors in Panoptes Pharma
Panoptes Pharma has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Austria Wirtschaftsservice and EyeGate.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Banking regulatory services are provided for Austrian financial institutions. | 2002 | aws.at | Vienna, Austria | |
Therapeutics and drug delivery systems for eye diseases are developed. | 1998 | eyegatepharma.com | Waltham, United States |
Investor details for Panoptes Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Panoptes Pharma
4 dated milestones of Panoptes Pharma across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Panoptes Pharma is founded.
- Funding First funding round of $1.6M.
- Funding Latest funding round, Series A,.
- Exit Acquired by EyeGate.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Panoptes Pharma
Panoptes Pharma was founded in 2013.
Panoptes Pharma is headquartered in Vienna, Austria.
Panoptes Pharma is a funded company, having raised a total of $1.62M across 2 funding rounds to date. The company's 1st funding round was a Seed of $1.62M, raised on Sep 2013.
Panoptes Pharma was established in 2013 in Vienna, Austria, within the pharmaceutical sector. Small molecule-based treatments are developed for eye conditions with significant unmet needs, including autoimmune uveitis and inflammatory diseases. The lead candidate, PP-001, functions as a specific inhibitor of an enzyme in the de novo pyrimidine pathway and is undergoing preclinical trials for uveitis and viral conjunctivitis. Operations center on advancing these therapies through clinical development.
Panoptes Pharma offers PP-001, Augentropfen, Injektionen, and Systemische Arzneimittel.
Panoptes Pharma has 2 investors. Key investors include Austria Wirtschaftsservice, and EyeGate.
Yes. Panoptes Pharma was acquired by EyeGate in December 2020.